

MM Glossary and Reference

Glossary

1st-Gen, first generation	LEN, lenalidomide
2d-Gen, second generation	mAb, monoclonal antibody
ADLs, activities of daily life	MM, multiple myeloma
AEs, adverse effects/events	MOA, mechanism of action
ASCO/CCO, American Society of Clinical Oncology/ Cancer Care Ontario	mos, months
ASCT, autologous stem cell transplant	mPFS, median progression-free survival
β_2 M, beta-2 microglobulin	M-protein, monoclonal protein
BIW, twice per week	MRI, magnetic resonance imaging
BOR, bortezomib	NCCN, National Comprehensive Cancer Network
CAR, carfilzomib	NDMM, newly diagnosed multiple myeloma
CR, complete response	ORR, overall response rate
del(17p), deletion of short arm of chromosome 17	OS, overall survival
DEX, dexamethasone	PET/CT, positron emission tomography/computed tomography
DRd, daratumumab/lenalidomide/dexamethasone	PFS, progression-free survival
DVMp, daratumumab/bortezomib /melphalan/prednisone	PI(s), proteasome inhibitor(s)
Dx, diagnosis	PN, peripheral neuropathy
FISH, fluorescence in situ hybridization	PRN, pro re nata (as needed)
H2H, head to head	PVd, pomalidomide/bortezomib/dexamethasone
Hb, hemoglobin	pt(s), patient(s)
HRQOL, health-related quality of life	QOL, quality of life
Hx, history	QW, once per week
Id, ixazomib/dexamethasone	RCT, randomized clinical trial
IDd, daratumumab/ixazomib/dexamethasone	Rd, lenalidomide/dexamethasone
IFE, immunofixation electrophoresis	R-ISS, Revised International Staging System
IgA, immunoglobulin A	RR, reference range
IgG, immunoglobulin G	RRMM, relapsed/refractory multiple myeloma
IMiD, immunomodulatory imide drug	SC, subcutaneous
IPd, ixazomib/pomalidomide/dexamethasone	SDM, shared decision making
IRd, ixazomib/lenalidomide/dexamethasone	t(4;14), translocation of gene segments from chromosome 4 to chromosome 14
ISS, International Staging System	t(12;20), translocation of gene segments from chromosome 12 to chromosome 20
IV, intravenous	Tx, treatment/therapy
IXA, ixazomib	ULN, upper limit of normal
Kd, carfilzomib/dexamethasone	Vd, bortezomib/dexamethasone
KRd, carfilzomib/lenalidomide/dexamethasone	VRd, bortezomib/lenalidomide/dexamethasone
LDH, lactate dehydrogenase	

MM Glossary and Reference

References

- Campo C, da Silva Filho MI, Weinhold N, et al. Bortezomib-induced peripheral neuropathy: a genome-wide association study on multiple myeloma patients. *Hematol Oncol*. 2018;36:232-237.
- Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicenter study. *Lancet Oncol*. 2016;17:27-38.
- Dimopoulos MA, Oriol A, Nahi H, et al; POLLUX Investigators. Daratumumab, lenalidomide and dexamethasone for multiple myeloma. *N Engl J Med*. 2016;375:1319-1331.
- Dimopoulos MA, Stewart AK, Masszi T, et al. Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment. *Blood Cancer J*. 2017;7:e554.
- Dimopoulos MA, Terpos E, Niesvizky R, Palumbo A. Clinical characteristics of patients with relapsed multiple myeloma. *Cancer Treat Rev*. 2015;41:827-835.
- Durie BGM, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. *Leukemia*. 2006;20:1467-1473.
- Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. *J Clin Oncol*. 2005;23:3412-3420.
- Hu B, Zhou Q, Wu T, et al. Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis. *Int J Clin Pharmacol Ther*. 2017;55:329-338.
- Kyprolis® [package insert]. Thousand Oaks, CA: Amgen Inc.; 2018.
- Leleu X, Masszi T, Bahlis NJ, et al. Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib–lenalidomide–dexamethasone versus placebo–lenalidomide–dexamethasone in relapsed/refractory multiple myeloma. *Am J Hematol*. 2018 May 4. [Epub ahead of print]
- Ludwig H, Moreau P, Dimopoulos MA. Health-related quality of life in the ENDEAVOR study: carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed/refractory multiple myeloma. *Blood Cancer J*. 2019;9:23.
- Ludwig H, Spencer A, Kovacsics T, et al. Comparison of proteasome inhibition activity between carfilzomib and bortezomib in the phase 3 Endeavor study. *Blood*. 2017;130:3125.
- Mateos M-V, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. *N Engl J Med*. 2018;378:518-528.
- Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. *J Clin Oncol*. 2019;37:112-1263.
- Mikhael J, Ismaila N, Martin T. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline summary. *J Oncol Pract*. 2019;15:279-286.
- Moreau P, Masszi N, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*. 2016;374:17:1621-1634.
- Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. *Lancet Oncol*. 2018;19:953-964.
- National Comprehensive Cancer Network (NCC). NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma. Version 1.2020—September 6, 2019. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed October 3, 2019.
- Ninlaro® [package insert]. Cambridge, MA: Takeda Pharmaceutical Company Limited; 2016.
- Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from the International Myeloma Working Group. *J Clin Oncol*. 2015;33:2863-2869.
- Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. *N Engl J Med*. 2016;375:754-766.
- Peng L, Ye X, Zhou Y, Zhang J, Zhao Q. Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib. *Support Care Cancer*. 2015;23:2813-2824.
- Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol*. 2014;15:e538-e548.
- Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification and management. *Am J Hematol*. 2016;91:719-734.
- Richardson PG, Oriol A, Beksac M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory myeloma previously treated with lenalidomide (OPTIMISMM): a randomized, open-label, phase 3 trial. *Lancet Oncol*. 2019;20:781-794.
- Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. *Blood*. 2016;127:2955-2962.
- Spencer A, Lentzsch S, Weisel K, et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. *Haematologica*. 2018;103:2079-2087.
- Velcade® [package insert]. Cambridge, MA: Millennium Pharmaceuticals, Inc.; 2017.